3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Lymphoma
2
Sarcoma
1
Prostatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mixed Dementias
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Lewy Body Disease
1
Kidney Neoplasms
1
Dementia, Vascular
1
Dementia
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Breast Neoplasms
1
Interventions
Sunitinib
19
Everolimus
17
Bevacizumab
13
aldesleukin
11
Sorafenib
11
Interleukin-2
10
Cyclophosphamide
10
Axitinib
10
Nivolumab
9
fludarabine phosphate
7
fludarabine
7
pembrolizumab
5
Gemcitabine
5
temsirolimus
4
pazopanib
4
Ipilimumab
4
peginterferon alfa-2b
3
durvalumab
3
cabozantinib
3
Radiosurgery
3
Interferon-alpha
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Filgrastim
3
Erlotinib Hydrochloride
3
Cryosurgery
3
vandetanib
2
spartalizumab
2
perflutren
2
ixabepilone
2
chiron
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Kidney Neoplasms
×
Referral and Consultation
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts